SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
KTTA

Pasithea Therapeutics Corp. (KTTA)

NASDAQ: KTTA · Real-Time Price · USD
Healthcare · Biotechnology
$0.46+$0.02 (+5.62%)
 
Market cap
$16.9M
Insider Score
Analyst consensus
Market Cap$16.86M-30.5%
Revenue (ttm)n/a
Net Income-$24.83M
EPS-$1.59
Shares Out36.75M
PE Ration/a
Forward PE-1.00
Dividendn/a
Ex-Dividend Daten/a
Volume309,422
Open$0.45
Previous Close$0.43
Day's Range$0.45 - $0.47
52-Week Range$0.28 - $2.06
Betan/a
AnalystsStrong Buy
Price Target$4.00(+772.03%)
Earnings Daten/a
+5.92% (1D)
No price history available.

About KTTA

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Address
1111 Lincoln Road, Miami Beach, FL, 33139, United States
Market Cap
17 million
Employees
5
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$805.94K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

1 Day
+5.69%
5 Days
-13.78%
1 Month
+11.88%
6 Months
-36.47%
1 Year
-30.50%

$KTTA stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in KTTA holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by KTTA's directors and management

Net Shares Purchased by Insiders−2M−1M02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

KTTA Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New KTTA patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to KTTA from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from KTTA’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
0
Analyst Ratings
40% of score
99
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
3
Sells
0
Buy Value
$805.94K
Distinct Buyers
1

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.